Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 405

1.

Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma.

Rimassa L, Danesi R, Pressiani T, Merle P.

Cancer Treat Rev. 2019 Jul;77:20-28. doi: 10.1016/j.ctrv.2019.05.004. Epub 2019 May 15. Review.

2.

Appropriateness of repetitive therapeutic drug monitoring and laboratory turnaround time.

Sarli V, Ciofi L, Lastella M, Muscatello B, Pisaturo F, Paolilli O, Luci G, Cucchiara F, Pellegrini G, Bocci G, Danesi R, Di Paolo A.

Clin Chem Lab Med. 2019 Jun 11. pii: /j/cclm.ahead-of-print/cclm-2019-0429/cclm-2019-0429.xml. doi: 10.1515/cclm-2019-0429. [Epub ahead of print] No abstract available.

PMID:
31188753
3.

Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success.

Cazzaniga ME, Danesi R, Girmenia C, Invernizzi P, Elvevi A, Uguccioni M; NetworkER+.

Breast Cancer Res Treat. 2019 Aug;176(3):483-494. doi: 10.1007/s10549-019-05261-5. Epub 2019 May 7. Review.

4.

AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer.

Del Re M, Crucitta S, Sbrana A, Rofi E, Paolieri F, Gianfilippo G, Galli L, Falcone A, Morganti R, Porta C, Efstathiou E, van Schaik R, Jenster G, Danesi R.

BJU Int. 2019 May 4. doi: 10.1111/bju.14792. [Epub ahead of print]

PMID:
31055861
5.

The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report.

Del Re M, Rofi E, Cappelli C, Puppo G, Crucitta S, Valeggi S, Chella A, Danesi R, Petrini I.

BMC Cancer. 2019 Apr 30;19(1):410. doi: 10.1186/s12885-019-5604-6.

6.

From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.

Bordi P, Del Re M, Minari R, Rofi E, Buti S, Restante G, Squadrilli A, Crucitta S, Casartelli C, Gnetti L, Azzoni C, Bottarelli L, Petrini I, Cosenza A, Ferri L, Rapacchi E, Danesi R, Tiseo M.

Lung Cancer. 2019 May;131:78-85. doi: 10.1016/j.lungcan.2019.03.017. Epub 2019 Mar 19.

PMID:
31027702
7.

Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence.

Macera L, Spezia PG, Medici C, Rofi E, Del Re M, Focosi D, Mazzetti P, Navarro D, Antonelli G, Danesi R, Pistello M, Maggi F.

J Med Virol. 2019 Apr 19. doi: 10.1002/jmv.25488. [Epub ahead of print]

PMID:
31002743
8.

Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes.

Allegra S, Di Paolo A, Cusato J, Fatiguso G, Arrigoni E, Danesi R, Corcione S, DʼAvolio A.

Ther Drug Monit. 2019 Apr;41(2):254-255. doi: 10.1097/FTD.0000000000000596. No abstract available.

PMID:
30883522
9.

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.

Del Re M, Cinieri S, Michelucci A, Salvadori S, Loupakis F, Schirripa M, Cremolini C, Crucitta S, Barbara C, Di Leo A, Latiano TP, Pietrantonio F, Di Donato S, Simi P, Passardi A, De Braud F, Altavilla G, Zamagni C, Bordonaro R, Butera A, Maiello E, Pinto C, Falcone A, Mazzotti V, Morganti R, Danesi R.

Pharmacogenomics J. 2019 Feb 6. doi: 10.1038/s41397-019-0077-1. [Epub ahead of print]

10.

Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors.

Fogli S, Del Re M, Curigliano G, van Schaik RH, Lancellotti P, Danesi R.

Cancer Treat Rev. 2019 Mar;74:21-28. doi: 10.1016/j.ctrv.2019.01.006. Epub 2019 Jan 19. Review.

11.

Rebuttal letter: Different underlying mechanism might explain the absence of a significant difference in AUC of linezolid for different ABCB1 genotypes.

Allegra S, Di Paolo A, Cusato J, Fatiguso G, Arrigoni E, Danesi R, Corcione S, DʼAvolio A.

Ther Drug Monit. 2019 Jan 9. doi: 10.1097/FTD.0000000000000596. [Epub ahead of print] No abstract available.

PMID:
30633091
12.

The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer.

Rofi E, Vivaldi C, Del Re M, Arrigoni E, Crucitta S, Funel N, Fogli S, Vasile E, Musettini G, Fornaro L, Falcone A, Danesi R.

Pharmacogenomics. 2019 Jan;20(1):49-68. doi: 10.2217/pgs-2018-0149. Epub 2018 Dec 6.

PMID:
30520336
13.

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.

Cremolini C, Rossini D, Dell'Aquila E, Lonardi S, Conca E, Del Re M, Busico A, Pietrantonio F, Danesi R, Aprile G, Tamburini E, Barone C, Masi G, Pantano F, Pucci F, Corsi DC, Pella N, Bergamo F, Rofi E, Barbara C, Falcone A, Santini D.

JAMA Oncol. 2018 Nov 21. doi: 10.1001/jamaoncol.2018.5080. [Epub ahead of print]

PMID:
30476968
14.

Radiomics and liquid biopsy in oncology: the holons of systems medicine.

Neri E, Del Re M, Paiar F, Erba P, Cocuzza P, Regge D, Danesi R.

Insights Imaging. 2018 Dec;9(6):915-924. doi: 10.1007/s13244-018-0657-7. Epub 2018 Nov 14. Review.

15.

The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response.

Del Re M, Bordi P, Rofi E, Restante G, Valleggi S, Minari R, Crucitta S, Arrigoni E, Chella A, Morganti R, Tiseo M, Petrini I, Danesi R.

Br J Cancer. 2018 Nov;119(10):1252-1258. doi: 10.1038/s41416-018-0238-z. Epub 2018 Nov 6.

PMID:
30397287
16.

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.

Cuneo A, Barosi G, Danesi R, Fagiuoli S, Ghia P, Marzano A, Montillo M, Poletti V, Viale P, Zinzani PL.

Hematol Oncol. 2019 Feb;37(1):3-14. doi: 10.1002/hon.2540. Epub 2018 Sep 5. Review.

17.

The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review.

Matucci A, Vultaggio A, Danesi R.

Respir Res. 2018 Aug 16;19(1):154. doi: 10.1186/s12931-018-0859-z. Review.

18.

Predicting fluoropyrimidine-related toxicity: turning wish to will, the PAMM-EORTC position.

Ciccolini J, Del Re M, Danesi R, Milano G, Schellens JHM, Raymond E.

Ann Oncol. 2018 Sep 1;29(9):1893-1894. doi: 10.1093/annonc/mdy258. No abstract available.

PMID:
30032203
19.

A Common mdr1 Gene Polymorphism is Associated With Changes in Linezolid Clearance.

Allegra S, Di Paolo A, Cusato J, Fatiguso G, Arrigoni E, Danesi R, Corcione S, DʼAvolio A.

Ther Drug Monit. 2018 Oct;40(5):602-609. doi: 10.1097/FTD.0000000000000536.

PMID:
29979333
20.

EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance.

Fogli S, Polini B, Del Re M, Petrini I, Passaro A, Crucitta S, Rofi E, Danesi R.

Pharmacogenomics. 2018 Jun 1;19(8):727-740. doi: 10.2217/pgs-2018-0038. Epub 2018 May 22. Review.

PMID:
29785875
21.

Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment.

Del Re M, Crucitta S, Restante G, Rofi E, Arrigoni E, Biasco E, Sbrana A, Coppi E, Galli L, Bracarda S, Santini D, Danesi R.

Crit Rev Oncol Hematol. 2018 May;125:51-59. doi: 10.1016/j.critrevonc.2018.03.002. Epub 2018 Mar 6. Review.

PMID:
29650277
22.

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC.

Del Re M, Marconcini R, Pasquini G, Rofi E, Vivaldi C, Bloise F, Restante G, Arrigoni E, Caparello C, Bianco MG, Crucitta S, Petrini I, Vasile E, Falcone A, Danesi R.

Br J Cancer. 2018 Mar 20;118(6):820-824. doi: 10.1038/bjc.2018.9. Epub 2018 Mar 6.

23.

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer.

Cremolini C, Del Re M, Antoniotti C, Lonardi S, Bergamo F, Loupakis F, Borelli B, Marmorino F, Citi V, Cortesi E, Moretto R, Ronzoni M, Tomasello G, Zaniboni A, Racca P, Buonadonna A, Allegrini G, Ricci V, Di Donato S, Zagonel V, Boni L, Falcone A, Danesi R.

Oncotarget. 2017 Dec 21;9(8):7859-7866. doi: 10.18632/oncotarget.23559. eCollection 2018 Jan 30.

24.

Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.

Citi V, Del Re M, Martelli A, Calderone V, Breschi MC, Danesi R.

Cancer Chemother Pharmacol. 2018 Apr;81(4):745-754. doi: 10.1007/s00280-018-3543-6. Epub 2018 Feb 23.

PMID:
29476223
25.

Implications of KRAS mutations in acquired resistance to treatment in NSCLC.

Del Re M, Rofi E, Restante G, Crucitta S, Arrigoni E, Fogli S, Di Maio M, Petrini I, Danesi R.

Oncotarget. 2017 Dec 21;9(5):6630-6643. doi: 10.18632/oncotarget.23553. eCollection 2018 Jan 19. Review.

26.

Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment.

Arrigoni E, Del Re M, Galimberti S, Restante G, Rofi E, Crucitta S, Baratè C, Petrini M, Danesi R, Di Paolo A.

Stem Cells Transl Med. 2018 Mar;7(3):305-314. doi: 10.1002/sctm.17-0175. Epub 2018 Feb 8. Review.

27.

Clinical pharmacology of intravitreal anti-VEGF drugs.

Fogli S, Del Re M, Rofi E, Posarelli C, Figus M, Danesi R.

Eye (Lond). 2018 Jun;32(6):1010-1020. doi: 10.1038/s41433-018-0021-7. Epub 2018 Feb 5. Review.

28.

Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells.

Del Re M, Arrigoni E, Restante G, Passaro A, Rofi E, Crucitta S, De Marinis F, Di Paolo A, Danesi R.

Stem Cells. 2018 May;36(5):633-640. doi: 10.1002/stem.2787. Epub 2018 Feb 5. Review.

29.

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.

Minari R, Bordi P, Del Re M, Facchinetti F, Mazzoni F, Barbieri F, Camerini A, Comin CE, Gnetti L, Azzoni C, Nizzoli R, Bortesi B, Rofi E, Petreni P, Campanini N, Rossi G, Danesi R, Tiseo M.

Lung Cancer. 2018 Jan;115:21-27. doi: 10.1016/j.lungcan.2017.11.011. Epub 2017 Nov 13.

PMID:
29290257
30.

Individualized dosing with axitinib: rationale and practical guidance.

Schmidinger M, Danesi R, Jones R, McDermott R, Pyle L, Rini B, Négrier S.

Future Oncol. 2018 Apr;14(9):861-875. doi: 10.2217/fon-2017-0455. Epub 2017 Dec 21. Review.

31.

Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment.

Del Re M, Bordi P, Petrini I, Rofi E, Mazzoni F, Belluomini L, Vasile E, Restante G, Di Costanzo F, Falcone A, Frassoldati A, van Schaik RHN, Steendam CMJ, Chella A, Tiseo M, Morganti R, Danesi R.

Oncotarget. 2017 Sep 15;8(49):86056-86065. doi: 10.18632/oncotarget.20947. eCollection 2017 Oct 17.

32.

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.

Galimberti S, Bucelli C, Arrigoni E, Baratè C, Grassi S, Ricci F, Guerrini F, Ciabatti E, Fava C, D'Avolio A, Fontanelli G, Cambrin GR, Isidori A, Loscocco F, Caocci G, Greco M, Bocchia M, Aprile L, Gozzini A, Scappini B, Cattaneo D, Scortechini AR, La Nasa G, Bosi A, Leoni P, Danesi R, Saglio G, Visani G, Cortelezzi A, Petrini M, Iurlo A, Di Paolo A.

Oncotarget. 2017 Sep 30;8(50):88021-88033. doi: 10.18632/oncotarget.21406. eCollection 2017 Oct 20.

33.

Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.

Schmidinger M, Danesi R.

Oncologist. 2018 Mar;23(3):306-315. doi: 10.1634/theoncologist.2017-0335. Epub 2017 Nov 16. Review.

34.

Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life.

Matrone A, Valerio L, Pieruzzi L, Giani C, Cappagli V, Lorusso L, Agate L, Puleo L, Viola D, Bottici V, Del Re M, Molinaro E, Danesi R, Elisei R.

Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):319-334. doi: 10.1016/j.beem.2017.06.001. Epub 2017 Jun 15. Review.

PMID:
28911728
35.

Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule.

Di Paolo A, Bracarda S, Arrigoni E, Danesi R.

Front Pharmacol. 2017 Aug 7;8:523. doi: 10.3389/fphar.2017.00523. eCollection 2017. No abstract available.

36.

Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer.

Del Re M, Vivaldi C, Rofi E, Vasile E, Miccoli M, Caparello C, d'Arienzo PD, Fornaro L, Falcone A, Danesi R.

Sci Rep. 2017 Aug 11;7(1):7931. doi: 10.1038/s41598-017-08297-z.

37.

Reply to Ugo De Giorgi, Vincenza Conteduca, and Emanuela Scarpi's Letter to the Editor re: Marzia Del Re, Elisa Biasco, Stefania Crucitta, et al. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2017;71:680-7.

Del Re M, Biasco E, Crucitta S, Derosa L, Rofi E, Orlandini C, Miccoli M, Galli L, Falcone A, Jenster GW, van Schaik RH, Danesi R.

Eur Urol. 2018 Jan;73(1):e11-e12. doi: 10.1016/j.eururo.2017.07.034. Epub 2017 Aug 9. No abstract available.

PMID:
28801127
38.

Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.

Gridelli C, Ardizzoni A, Barberis M, Cappuzzo F, Casaluce F, Danesi R, Troncone G, De Marinis F.

Transl Lung Cancer Res. 2017 Jun;6(3):373-386. doi: 10.21037/tlcr.2017.05.09. Review.

39.

Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: a case report with pharmacogenetic analysis to personalize treatment.

Del Re M, Latiano T, Fidilio L, Restante G, Morelli F, Maiello E, Danesi R.

EPMA J. 2017 Mar 7;8(1):69-73. doi: 10.1007/s13167-017-0080-z. eCollection 2017 Mar.

40.

Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.

Bordi P, Tiseo M, Rofi E, Petrini I, Restante G, Danesi R, Del Re M.

Clin Lung Cancer. 2017 Nov;18(6):692-697. doi: 10.1016/j.cllc.2017.04.013. Epub 2017 May 18.

PMID:
28601386
41.

Should CYP2D6 be genotyped when treating with tamoxifen?

Del Re M, Rofi E, Citi V, Fidilio L, Danesi R.

Pharmacogenomics. 2017 Jun;18(8):755-756. doi: 10.2217/pgs-2017-0065. Epub 2017 Jun 8.

PMID:
28593824
42.

Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors.

Antonuzzo L, Del Re M, Barucca V, Spada F, Meoni G, Restante G, Danesi R, Di Costanzo F, Fazio N.

Cancer Treat Rev. 2017 Jun;57:28-35. doi: 10.1016/j.ctrv.2017.05.001. Epub 2017 May 11. Review.

PMID:
28535439
43.

Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer.

Tedaldi G, Tebaldi M, Zampiga V, Danesi R, Arcangeli V, Ravegnani M, Cangini I, Pirini F, Petracci E, Rocca A, Falcini F, Amadori D, Calistri D.

Oncotarget. 2017 Jul 18;8(29):47064-47075. doi: 10.18632/oncotarget.16791.

44.

The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide.

Del Re M, Fogli S, Derosa L, Massari F, De Souza P, Crucitta S, Bracarda S, Santini D, Danesi R.

Cancer Treat Rev. 2017 Apr;55:71-82. doi: 10.1016/j.ctrv.2017.03.001. Epub 2017 Mar 9. Review.

PMID:
28340451
45.

Determinants of bone specific metastasis in prostate cancer.

Manca P, Pantano F, Iuliani M, Ribelli G, De Lisi D, Danesi R, Del Re M, Vincenzi B, Tonini G, Santini D.

Crit Rev Oncol Hematol. 2017 Apr;112:59-66. doi: 10.1016/j.critrevonc.2017.02.013. Epub 2017 Feb 16. Review.

PMID:
28325265
46.

Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.

Galeotti L, Ceccherini F, Domingo D, Laurino M, Polillo M, Di Paolo A, Baratè C, Fava C, D'Avolio A, Cervetti G, Guerrini F, Fontanelli G, Ciabatti E, Grassi S, Arrigoni E, Danesi R, Petrini M, Cornolti F, Saglio G, Galimberti S.

Cancer Chemother Pharmacol. 2017 Apr;79(4):767-773. doi: 10.1007/s00280-017-3271-3. Epub 2017 Mar 13.

PMID:
28289867
47.

The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.

Declerck P, Danesi R, Petersel D, Jacobs I.

Drugs. 2017 Apr;77(6):671-677. doi: 10.1007/s40265-017-0717-1. Review.

48.

BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype.

Zuntini R, Cortesi L, Calistri D, Pippucci T, Martelli PL, Casadio R, Capizzi E, Santini D, Miccoli S, Medici V, Danesi R, Marchi I, Zampiga V, Fiorentino M, Ferrari S, Turchetti D.

Oncotarget. 2017 Apr 4;8(14):22640-22648. doi: 10.18632/oncotarget.15151.

49.

Melanocortin Receptor-4 Gene Polymorphisms in Glioblastoma Patients Treated with Concomitant Radio-Chemotherapy.

Pasqualetti F, Orlandi P, Simeon V, Cantarella M, Giuliani D, Di Desidero T, Gonnelli A, Delishaj D, Lombardi G, Sechi A, Sanson M, Zagonel V, Paiar F, Danesi R, Guarini S, Bocci G.

Mol Neurobiol. 2018 Feb;55(2):1396-1404. doi: 10.1007/s12035-017-0414-9. Epub 2017 Feb 1.

PMID:
28150230
50.

IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.

Di Salvatore M, Pietrantonio F, Orlandi A, Del Re M, Berenato R, Rossi E, Caporale M, Guarino D, Martinetti A, Basso M, Mennitto R, Santonocito C, Mennitto A, Schinzari G, Bossi I, Capoluongo E, Danesi R, de Braud F, Barone C.

Oncotarget. 2017 Mar 7;8(10):16887-16898. doi: 10.18632/oncotarget.14810.

Supplemental Content

Loading ...
Support Center